peoplePerson
Vijay Patil
Showed that very low-dose nivolumab added to cheap chemotherapy improves survival in head and neck cancer, a landmark for affordable immunotherapy.
Vijay Patil led the randomised trial of low-dose nivolumab (20 mg every 3 weeks) added to triple metronomic chemotherapy in advanced head and neck cancer, showing an overall survival benefit at a fraction of standard-dose cost.
Role
Professor of Medical Oncology, Tata Memorial Hospital; head and neck oncology
Institution
Specialisms
Head and neck cancerLow-dose immunotherapyMetronomic chemotherapyPragmatic trials
| Title | Journal | Year |
|---|---|---|
| Low-dose immunotherapy in head and neck cancer: a randomized study | Journal of Clinical Oncology | 2023 |